Theravance Biopharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TBPH and other ETFs, options, and stocks.

About TBPH

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. 

CEO
Rick E. Winningham
CEORick E. Winningham
Employees
97
Employees97
Headquarters
South San, California
HeadquartersSouth San, California
Founded
2013
Founded2013
Employees
97
Employees97

TBPH Key Statistics

Market cap
692.18M
Market cap692.18M
Price-Earnings ratio
24.29
Price-Earnings ratio24.29
Dividend yield
Dividend yield
Average volume
1.08M
Average volume1.08M
High today
$13.90
High today$13.90
Low today
$13.40
Low today$13.40
Open price
$13.54
Open price$13.54
Volume
618.81K
Volume618.81K
52 Week high
$21.03
52 Week high$21.03
52 Week low
$7.90
52 Week low$7.90

Stock Snapshot

The current Theravance Biopharma(TBPH) stock price is $13.66, with a market capitalization of 692.18M. The stock trades at a price-to-earnings (P/E) ratio of 24.29.

On 2026-03-05, Theravance Biopharma(TBPH) stock moved within a range of $13.40 to $13.90. With shares now at $13.66, the stock is trading +1.9% above its intraday low and -1.7% below the session's peak.

Trading activity shows a volume of 618.81K, compared to an average daily volume of 1.08M.

Over the past 52 weeks, Theravance Biopharma(TBPH) stock has traded between a high of $21.03 and a low of $7.90.

Over the past 52 weeks, Theravance Biopharma(TBPH) stock has traded between a high of $21.03 and a low of $7.90.

TBPH News

TipRanks 1h
Theravance Biopharma downgraded to Perform from Outperform at Oppenheimer

Oppenheimer analyst Trevor Allred downgraded Theravance Biopharma (TBPH) to Perform from Outperform. Published first on TheFly – the ultimate source for real-t...

TipRanks 1d
Theravance Biopharma downgraded to Neutral from Buy at B. Riley

B. Riley downgraded Theravance Biopharma (TBPH) to Neutral from Buy with a price target of $14, down from $28. The company reported that the Phase 3 CYPRESS stu...

TipRanks 2d
Theravance Biopharma Restructures After Ampreloxetine Trial Failure

Theravance Biopharma ( (TBPH) ) has provided an announcement. On March 3, 2026, Theravance Biopharma reported that its Phase 3 CYPRESS trial of ampreloxetine i...

Analyst ratings

57%

of 7 ratings
Buy
57.1%
Hold
42.9%
Sell
0%

People also own

Based on the portfolios of people who own TBPH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.